Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 67

Results For "MANA"

2424 News Found

Dr Mandaviya launches Credit Assistance Program for Jan Aushadhi Kendras
Policy | March 13, 2024

Dr Mandaviya launches Credit Assistance Program for Jan Aushadhi Kendras

From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today


AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine
News | March 12, 2024

AstraZeneca Pharma India, Mankind Pharma ink pact to distribute asthma medicine

India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.


Nectar Lifesciences’ suo moto clarification on a news item
News | March 07, 2024

Nectar Lifesciences’ suo moto clarification on a news item

Nectar Lifesciences has clarified that the company has no relation/connection/ association or link of any nature with the Nectar Herbs and Drugs


Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer
People | March 07, 2024

Aurobindo Pharma appoints N. Ravikiran as Chief Business Officer

Earlier, he worked with Cadila Pharmaceuticals Limited, Cipla, Alkem Laboratories, and Wockhardt, and started his career with Novartis


Dr. Lal PathLabs CEO Bharath Uppilliappan steps down
People | March 07, 2024

Dr. Lal PathLabs CEO Bharath Uppilliappan steps down

Uppilliappan joined Dr. Lal Pathlabs in 2016 as Chief Operating Officer and later became CEO


Amita Sharma redesignated As COO- API at Morepen Lab
People | March 07, 2024

Amita Sharma redesignated As COO- API at Morepen Lab

Sharma joined the Morepen Lab in 2004


Warren Remedies commences commercial production of oral care products
News | March 02, 2024

Warren Remedies commences commercial production of oral care products

The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra


Suven announces merger of Cohance Lifesciences
News | March 01, 2024

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals